LinkedIn Image

Navigating Treatment Decisions in Metastatic Pancreatic Cancer

Meeting Overview

Engage with experts in the field of metastatic pancreatic adenocarcinoma by joining this highly interactive satellite symposium. You will gain expert insights on how to select first-line treatment based on evidence and current guidelines, and learn about the optimal management for patients with progressive metastatic pancreatic adenocarcinoma. Furthermore, you will gain insight on the high prevalence of malnutrition in patients with the disease, and the importance of early nutrition intervention. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Satellite Symposium held in conjunction with the ESMO 19th World Congress on Gastrointestinal Cancer. This symposium content is not an official part of the World Congress scientific program, nor is it organized or endorsed by Imedex.

Agenda

13.20 Welcome and introduction
Michel Ducreux, MD, PhD

Setting the stage: Accomplishments and challenges in the management of metastatic pancreatic adenocarcinoma
Michel Ducreux, MD, PhD

13.30 Case 1—Metastatic pancreatic adenocarcinoma: What therapy should I select first?
Marc Peeters, MD, PhD
13.48 Faculty panel commentary and audience questions
13.55 Case 2—Optimal management of progressive metastatic pancreatic adenocarcinoma: Second-line therapy and beyond
Gerald Prager, MD
14.13 Faculty panel commentary and audience questions
14.20 Importance of nutrition in pancreatic cancer care
Federico Bozzetti, MD
14.35 Faculty panel commentary and audience questions
14.40 Future perspectives and prIME Points™
Michel Ducreux, MD, PhD
14.50 Adjourn

Faculty

CHAIR
  • Michel Ducreux, MD, PhDGustave Roussy
    Villejuif, France
FACULTY
  • Federico Bozzetti, MDSurgical oncologist
    Milan, Italy
  • Marc Peeters, MD, PhDAntwerp University Hospital
    Antwerp, Belgium
  • Gerald Prager, MDMedical University of Vienna
    Vienna, Austria

Target Audience

This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers outside of United States involved in the management of patients with pancreatic cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select the most appropriate treatment approach for newly diagnosed metastatic pancreatic adenocarcinoma based on patient and disease characteristics
  • Identify optimal treatment strategies for patients with progressive pancreatic cancer (second-line therapy and beyond)
  • Assess supportive care measures including importance of nutrition throughout the course of pancreatic cancer management

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

Date and Location

Friday, 30 June 2017
13.20 – 14.50

Room: 111-112
Centre de Convencions Internacional de Barcelona (CCIB)
Plaça de Willy Brandt 11-14
Barcelona, Spain

Printed Materials

Printed Materials

Provider

This activity is provided by prIME Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Logo_IME_120

Support

This educational activity is supported by grants from Nutricia and Shire.

Sunshine/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.